Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Catalyst Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at $0.41 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 6.82% year-over-year to $0.41; the TTM value through Dec 2025 reached $1.69, up 29.01%, while the annual FY2025 figure was $1.68, 28.24% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.41 in Q4 2025 per CPRX's latest filing, down from $0.42 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.45 in Q1 2025 to a low of -$0.29 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.24, with a median of $0.24 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 245.0% in 2023, then surged 220.69% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.09 in 2021, then skyrocketed by 155.56% to $0.23 in 2022, then surged by 34.78% to $0.31 in 2023, then skyrocketed by 41.94% to $0.44 in 2024, then dropped by 6.82% to $0.41 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EPS (Weighted Average and Diluted) are $0.41 (Q4 2025), $0.42 (Q3 2025), and $0.41 (Q2 2025).